LifeMD, Inc. (NASDAQ:LFMD – Free Report) – Analysts at B. Riley issued their Q1 2025 EPS estimates for LifeMD in a research report issued to clients and investors on Tuesday, March 11th.

A new study found that fair prices for medications like Wegovy and Zepbound would be hundreds less per month than they are now. By Rebecca Robbins It’s easy to make a medical case for ...

ABC News' Dr. Tara Narula shares what patients need to know. Most compounded versions of popular drugs used for weight loss including Wegovy and Zepbound may soon no longer be available after a U ...

Most compounded versions of popular drugs used for weight loss including Wegovy and Zepbound may soon no longer be available after a U.S. judge declined an initial injunction to allow compounding ...

NEW YORK, March 06, 2025 (GLOBE NEWSWIRE) -- LifeMD, Inc. (Nasdaq: LFMD), a leading provider of virtual primary care services, today announced it is integrating with LillyDirect pharmacy provider ...

Teladoc Health is offering fertility, digestive health, and specialty care to its enterprise customers, the company said Tuesday. The virtual care company is partnering with Carrot Fertility for ...

Consolidated revenues increased 43% year-over-year to $64.3 million with telehealth revenue up 60%Adjusted EBITDA increased 78% to $9.0 millionTelehealth adjusted EBITDA increased 396% to $5.9 million ...

Tuesday saw KeyBanc Capital Markets reaffirm its Overweight rating on LifeMD Inc (NASDAQ:LFMD) stock, maintaining a price target of $7.50. The investment firm’s confidence in the telehealth provider ...

Steve Dechert; Analyst; KeyBanc Capital Markets Inc. Good afternoon. Thank you for joining us to discuss LifeMD Inc fourth-quarter and full-year 2024 earnings results. Joining the call today are ...

Good afternoon. Thank you for joining us to discuss LifeMD, Inc. Fourth Quarter and Full Year 2024 Earnings Results. Joining the call today are Justin Schreiber, Chairman and Chief Executive ...

The latest price target for LifeMD (NASDAQ:LFMD) was reported by HC Wainwright & Co. on March 12, 2025. The analyst firm set a price target for $14.00 expecting LFMD to rise to within 12 months (a ...